Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.

MLA

Kato, Renpei, et al. “Significance of Upfront Cytoreductive Nephrectomy Stratified by IMDC Risk for Metastatic Renal Cell Carcinoma in Targeted Therapy Era - a Multi-Institutional Retrospective Study.” International Journal of Clinical Oncology, vol. 27, no. 3, Mar. 2022, pp. 563–73. EBSCOhost, https://doi.org/10.1007/s10147-021-02091-8.

APA

Kato, R., Naito, S., Numakura, K., Hatakeyama, S., Koguchi, T., Kojima, T., Kawasaki, Y., Kandori, S., Kawamura, S., Arai, Y., Ito, A., Nishiyama, H., Kojima, Y., Ohyama, C., Habuchi, T., Tsuchiya, N., & Obara, W. (2022). Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study. International Journal of Clinical Oncology, 27(3), 563–573. https://doi.org/10.1007/s10147-021-02091-8

Chicago

Kato, Renpei, Sei Naito, Kazuyuki Numakura, Shingo Hatakeyama, Tomoyuki Koguchi, Takahiro Kojima, Yoshihide Kawasaki, et al. 2022. “Significance of Upfront Cytoreductive Nephrectomy Stratified by IMDC Risk for Metastatic Renal Cell Carcinoma in Targeted Therapy Era - a Multi-Institutional Retrospective Study.” International Journal of Clinical Oncology 27 (3): 563–73. doi:10.1007/s10147-021-02091-8.